Interstitial Lung Disease Research Unit Biobank (ILDRU)

September 16, 2025 updated by: Scott Matson, University of Kansas Medical Center

University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Recruiting
        • The University of Kansas Medical Center
        • Principal Investigator:
          • Chase Hall, M.D.
        • Sub-Investigator:
          • Scott Matson, M.D.
        • Sub-Investigator:
          • Mark Hamblin, M.D.
        • Sub-Investigator:
          • Sahil Pandya, M.D
        • Contact:
        • Sub-Investigator:
          • Janell Reichuber, APRN

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with ILD, RLD and subjects at risk for ILD

Description

Inclusion Criteria:

  1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
  2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
  3. The participant is ≥ 18 years of age.
  4. The participant has signed an approved consent for this study (living patients only)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research.
Time Frame: Enrollment to Year 10
Enrollment to Year 10
Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD.
Time Frame: Enrollment to Year 10
Enrollment to Year 10
Correlate biological samples with individual longitudinal clinical data.
Time Frame: Enrollment to Year 10
Enrollment to Year 10
Provide biological samples to researchers performing studies in ILD and RLD.
Time Frame: Enrollment to Year 10
Enrollment to Year 10
Collect historical data and imaging from deceased patients with ILD.
Time Frame: Enrollment to Year 10
Enrollment to Year 10

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Kansas Medical Center

Investigators

  • Principal Investigator: Scott Matson, M.D., University of Kansas Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 9, 2021

Primary Completion (Estimated)

August 1, 2031

Study Completion (Estimated)

March 1, 2032

Study Registration Dates

First Submitted

May 22, 2022

First Submitted That Met QC Criteria

May 22, 2022

First Posted (Actual)

May 26, 2022

Study Record Updates

Last Update Posted (Actual)

September 22, 2025

Last Update Submitted That Met QC Criteria

September 16, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00144558

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Contact Kimberly Lovell to discuss accessing IPD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Pulmonary Fibrosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe